NA-731™ for Traumatic Brain Injury (TBI)

A traumatic brain injury (TBI) refers to a brain injury that is caused by an outside force. TBI can be caused by a forceful bump, blow, or jolt to the head or body, or from an object entering the brain.

Some types of TBI can cause temporary or short-term problems with brain function, including problems with how a person thinks, understands, moves, communicates, and acts. More serious TBI can lead to severe and permanent disability, and even death.

Traumatic Brain Injury (TBI) is a condition, not a one-time event. Effective treatment of TBI represents a great unmet need in public health.

About 2.8 million people sustain TBI every year. It is the key factor to approximately 30% of all the injury-related fatalities in the United States of America. An estimated 5.3 million people live with the long-term physical, cognitive, and psychological health disabilities of TBI, with annual direct and indirect costs estimated at over $76 billion.

Although we are gaining ground in our understanding of the pathophysiology of TBI, these advances have failed to translate into a single successful clinical trial or treatment.

How does NA-731™ work?

Biomed team has developed a new drug, NA-731 for thr treatment of traumatic brain injury (TBI). NA-731 was designed based on neurogenesis method to catalyze the regeneration of new neurons in the hippocampus, thus, to offset the loss of damaged neurons in the brain.

NA-731™ is designed to stimulate neurogenesis and rescue the damaged motor neurons.

NA-731 has the following properties:

The Phase 2A clinical trials of NA-731 are being prepared to evaluate its safety and efficacy as required by the US Food and Drug Administration (FDA) and other regulators overseas before being approved for usage and marketing worldwide.